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Background: Impaired right ventricular (RV) function markedly impacts the prog-
nosis in patients (pts) with functional mitral regurgitation (FMR). In such pts, sig-
niﬁcant recovery of RV function after MitraClip (MC) therapy has been shown.
We sought to identify echocardiographic and/or hemodynamic variables predicting
recovery of RV function after MC therapy.
Methods: Of 194 pts with signiﬁcant FMR receiving MC therapy at our institution,
impaired RV function (deﬁned as tricuspid annular plane systolic excursion [TAPSE]
< 18mm) was present at baseline in 78 (40%). Six-week echocardiographic follow-up
was obtained from 36 pts (71  11 years; 23 men [64%]).
Results: Recovery of RV function – deﬁned as a change in TAPSE (DTAPSE)
>3mm – was observed at 6 weeks in 8/36 pts (22%). These 8 pts (mean DTAPSE
5.6  0.9mm) differed from the 28 pts with DTAPSE 3mm (mean DTAPSE
0.7  2.4mm) in baseline TAPSE (9.4  1.7mm vs. 12.2  2.5mm, respectively;
p¼0.005) and baseline cardiac output (4.4  1.3L/min vs. 3.2  1.0L/min, respec-
tively; p¼0.01). Normal baseline cardiac output (4.5L/min) was present in 50% of
pts with DTAPSE >3mm, yet only in 14% of pts with DTAPSE 3mm (p¼0.054).
No differences between the 2 groups were noted in terms of left ventricular (LV) end-
diastolic diameter, LV ejection fraction, systolic pulmonary artery pressure, capillary
wedge pressure, and MR severity at baseline. Univariate logistic regression analysis
for the end point of DTAPSE >3mm at 6 weeks revealed odds ratios of 1.85 (95%
conﬁdence interval, 1.11 – 3.03; p¼0.017) associated with a 1-mm decrease in
baseline TAPSE and 2.66 (1.15 – 6.18; p¼0.023) associated with a 1-L/min increase
in baseline cardiac output.
Conclusions: MC therapy for signiﬁcant FMR apparently leads to recovery of RV
function particularly in pts with markedly reduced baseline TAPSE yet unimpaired
cardiac output. Further study is warranted to verify these observations.TCT-796
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Background: There is a lack of knowledge on risk stratiﬁcation for Mitraclip patients.
Methods: To explore the adaptability of three contemporary surgical scores (Logistic
EuroSCORE [LES], EuroSCORE II [ESII] and Society of Thoracic Surgeons Pre-
dicted Risk of Mortality [STS-PROM] for prediction of mortality after percutaneous
mitral valve repair with the Mitraclip system.
Results: A statistically signiﬁcant gradient in the distribution of mortality was
observed at all time points with ESII, at 2 years with LES and at 2 and 3 years with
STS-PROM. ESII had the best discrimination at 30 days (c-statistic 0.80), which
remained acceptable at later follow-up, being signiﬁcantly superior to that of LES at
each time point (P¼0.003 at 30 days, P¼0.005 at 1 year, P¼0.011 at 2 years, P¼0.029
at 3 years). Compared with STS-PROM (c-statistic 0.62), ESII showed better
discrimination at 30 days (P¼0.023). All scores over-predicted the risk of mortality at
30 days and were miscalibrated at 2 and 3 years. At 1 year, there was a good
agreement between the observed and predicted probabilities for ESII and STS-PROM,
whereas LES remained over-predictive. ESII showed the best global accuracy at
30 days and 1 year, whereas no notable differences were noted versus LES and
STS-PROM at 2 and 3 years.
Conclusions: In the absence of speciﬁc tools for risk stratiﬁcation of patients un-
dergoing MitraClip implantation, ESII holds favorable prognostic characteristics,
which make it a valid surrogate.TCT-797
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Background: Percutaneous mitral valve repair using the MitraClip system has
gained increasingly acceptance in patients with signiﬁcant mitral regurgitation who areJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Valvulinegible or with disproportionately high risk for surgical intervention. However, data
about long-term follow up are rare, especially in those who are treated for functional
mitral regurgitation (FMR).
Methods: Procedural data, safety results and clinical outcomes, including mortality
rates, freedom from mitral valve (MV) surgery, reduction in MR, as well as im-
provements in NYHA Class, Six Minute Walk Test (6MWT), and Quality of Life
(QoL) were evaluated beyond at least 2 years after MitraClip procedure in patients
with FMR  3+ and symptomatic heart failure.
Results: From August 2009 to March 2014 we treated 50 patients with a percutaneous
catheter-based MitraClip system. In 45 patients signiﬁcant FMR grade 3+/4+ was
the indication of index procedure and in 95% (43/45) we could place 1 or more clips.
Up to now we have hemodynamic and clinical outcome data available in 30 sufﬁ-
ciently treated patients beyond at least 24 month after MitraClip procedure. 60% were
male, median age was 73.5 years (IQR 66.5-80), the logEuroscore I was mean
23.913.0% and NTpropBNP was median 5421 pg/ml(IQR 2877-12633). All of them
were highly symptomatic in NYHA class III/IV and 6 minute walktest (6 MWT) was
mean 181141 meters. The mean LVEF was 30.6812.2% and even 8 patients had
an LVEF< 25%. Survival rate at 24 month was 70% (21/30). The proportion of
patients with residual MR2 was 90%. One patient underwent heart transplantation
due to persistant heart failure symptoms although the the Clip procedure was suc-
cessful and residual MR was grade< 2. After 24 month the 6 MWT increased
and symptoms and NTproBNP decreased both signiﬁcantly. Even in a subgroup of
7/30 patients with a higly reduced LVEF< 25% surprisingly the survival rates was
62.5% (5/8).
Conclusions: Treatment with the MitraClip system in symptomatic patients with
severe FMR was effective with acceptable mortality rates despite multimorbidity.
Thus conﬁrms adequateness of this methode as an important non surgical option and
provide evidence for sustained efﬁcacy of MitraClip treatment.TCT-798
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Background: Transcatheter edge-to-edge repair has been demonstrated to be safe and
effective in degenerative mitral regurgitation and is currently approved for high risk
patients. The outcomes in patients with left ventricular dysfunction and functional
mitral regurgitation (MR) are currently being evaluated in clinical trial. We sought to
describe the outcomes of real-world patients with functional MR treated with the
MitraClip.
Methods: Single-center prospective registry of patients with signiﬁcant MR treated
with the MitraClip under the compassionate use program of Health Canada. Data was
collected on baseline demographics, echocardiographic parameters and clinical out-
comes including mortality, re-hospitalizations for congestive heart failure and post-
procedural MR.
Results: A total of 63 patients with symptomatic functional MR underwent therapy
with the MitraClip between December 2010 and February 2014. The mean age was
72.2 years with 76.2% males (n¼48) and 93.7% of patients in NYHA Class III-IV.
Patients were high surgical risk (mean logistic Euroscore-2 15%) due to comorbidities:
diabetes (44.4%), hypertension (61.9%), renal insufﬁciency (81%), and previous
cardiac surgery (55.6%). The mean LVEF was 33.612.8%. Procedural success,
deﬁned as reduction of MR to  2+, was achieved in 82.5% (n¼52 patients). At mean
follow up of 288 days, the mortality was 19% (12 patients), with a re-hospitalization
rate of 7.9% (5 patients).Conclusions: Transcatheter edge-to edge repair of the mitral valve in patients with
symptomatic functional MR is feasible, safe and has shown favorable outcomes in
real-world patients.ar disease - Mitraclip B233
